Internal Medicine, Rheumatology · Meadowbrook, PA
NPI
1841220662
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
1650 Huntingdon Pike, Suite 352
Meadowbrook, PA, 19046
Phone (267) 571-2151
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.4M
122,751 services
Medicare patients, 2024
396
Average age 73
Drug cost, 2024
$2.8M
2,998 prescriptions
Company payments, 2025
$296
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Deirdre A Reid-Fighera was code J0717 (injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 38,000 times for 12 patients. In total Deirdre A Reid-Fighera billed 122,751 services in 42 codes, and Medicare paid $1.4M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-07-06.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 38,000 | 12 | $3.61 | $137K |
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 12,810 | 11 | $8.57 | $110K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 10,750 | 12 | $33.89 | $364K |
| J0897 Injection, denosumab, 1 mg | Office | 8,340 | 84 | $20.47 | $171K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 4,670 | 11 | $23.54 | $110K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 425 | 47 | $0.10 | $43.25 |
| 96372 Injection Administration | Office | 392 | 105 | $11.99 | $4,699 |
| 99214 Office E&M - Established | Office | 361 | 187 | $94.39 | $34K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 268 | 160 | $12.74 | $3,415 |
| 96365 Intravenous Infusion, Hydration | Office | 213 | 47 | $52.48 | $11K |
| 99213 Office E&M - Established | Office | 175 | 142 | $68.55 | $12K |
| J3489 Injection, zoledronic acid, 1 mg | Office | 140 | 28 | $4.62 | $647 |
| 96413 Chemotherapy Administration | Office | 135 | 22 | $107.30 | $14K |
| 96415 Chemotherapy Administration | Office | 78 | 13 | $22.22 | $1,733 |
| 20610 Joint Injection | Office | 74 | 40 | $61.04 | $4,517 |
By year: 2022 $1.2M for 105,871 services; 2023 $1.4M for 124,002 services; 2024 $1.4M for 122,751 services.
Medicare prescription drug claims, 2024
In 2024, the drug Deirdre A Reid-Fighera prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 365 prescriptions and refills. In total Deirdre A Reid-Fighera wrote 2,998 Medicare prescriptions that cost $2.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 365 | 850 | 97 | $14K |
| Prednisone Generic | 298 | 507 | 73 | $2,739 |
| Methotrexate Methotrexate Sodium | 238 | 501 | 60 | $6,205 |
| Gabapentin Generic | 127 | 185 | 32 | $1,711 |
| Duloxetine Hcl Generic | 101 | 233 | 28 | $3,134 |
| Alendronate Sodium Generic | 96 | 197 | 24 | $605 |
| Meloxicam Generic | 96 | 200 | 35 | $353 |
| Methylprednisolone Generic | 92 | 118 | 52 | $1,402 |
| Enbrel Sureclick Etanercept | 91 | 115 | 14 | $875K |
| Sulfasalazine Generic | 91 | 213 | 32 | $3,477 |
| Allopurinol Generic | 83 | 181 | 21 | $1,118 |
| Tramadol Hcl Generic | 74 | 74 | 14 | $470 |
| Leflunomide Generic | 62 | 142 | 16 | $3,610 |
| Humira(Cf) Pen Adalimumab | 55 | 69 | Under 11 | $568K |
| Celecoxib Generic | 55 | 125 | 18 | $1,237 |
Brand drugs: 457 claims; generic drugs: 2,529 claims; opioid claims: 111.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Deirdre A Reid-Fighera $296 ($296 in general payments such as food, travel and fees) from 5 companies. The largest payer was Novartis Pharmaceuticals Corporation with $187.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.